Demonstrating Deep B-Cell Reset with CLN-978 by Translating Early Clinical Insights Moving Beyond Early Development
- Presenting emerging clinical data evaluating the safety, tolerability, and cytokine release syndrome profile of the CD19 x CD3 x HSA trispecific across autoimmune patient populations, establishing benchmarks for outpatient TCE administration
- Assessing the depth, durability, and tissue-level impact of B-cell depletion achieved through enhanced target engagement and extended half-life design, providing insight into the potential for sustained disease remission
- Translating clinical learnings on dosing, safety management, and biomarker evaluation into design principles for next-generation autoimmune T-cell engagers aimed at improving efficacy while minimizing treatment burden